Our Projects

Our platforM

We discovered a class of specialized RNAs interacting with the mammalian DNMT1 –  DNMT1-interacting RNAs (DiRs). DiRs prevent DNA methylation and gene silencing in a locus-specific manner, by binding and inhibiting DNMT1 .

RNA-guided platforms can be used to inhibit DNMT1 and diseases caused by aberrant DNA methylation.

APPLICATIONS

Selective and Gene-specific DNMT inhibitors in multiple disorders

Cancer

Lung (RASSF1;ESR1;MGMT), Breast (BRCA1, CDH1, MGMT, GSTP1, ESR1); Colon (P16;MGMT; GSTP1), Leukemia (P15; DAPK1; CDH1; ESR1), Prostate (GSTP1), Retinoblastoma (RB1) etc.

Genetic Diseases

Fragile X syndrome (FMR1); Myotonic dystrophy (DMPK); Prader Willi Syndrome (IPW); Amyotrophic Lateral Sclerosis (C9orf72); Retinoblastoma (RB); Lynch Syndrome (MLH1/EPM2AIP1) etc

Neurological Disorders

Alzheimer's disease (NEP)

Autoimmune Diseases

Reumathoid arthritis (SAT2; SAT3)

Pipeline

Oncology

MDS
NSCLC

Rare Disease

Fragile X

Metabolic Disorders

Not Disclosed